PTC Therapeutics at Wells Fargo conference: Sephiance drives growth plan

On Thursday, 10 September 2026, PTC Therapeutics (PTCT) utilized the Wells Fargo 21st Annual Healthcare Conference to present a business strategy transitioning away from older products and towards a broader rare disease portfolio. The company's management reported progress on revenue growth and cost control, but they also acknowledged declining sales from some legacy drugs and the need for clinical and regulatory success from several pipeline programs.

PTC's CEO, Matthew Klein, and CFO, Pierre Gravier, emphasized the company's aim to become a more profitable and diversified rare disease entity. CFO Gravier stated, "We want to build a diversified, sustainable business. You have to be profitable, no question. Rest assured that despite the fact that we have a number of early-stage programs coming and new development assets, there’s also the old programs coming out. We said we’re going to be very disciplined with OpEx, and that’s what we’ve been doing."

SEPHIANCE, also known as sepiapterin, remains the company's most significant near-term growth product. CEO Klein reported the launch, initiated about a year ago, is ahead of expectations in various aspects. He commented that early demand has come predominantly from therapy-naive patients, even those remote from clinics, who were previously considered challenging to treat.

Around 2,500 patients are currently on KUVAN, both branded and generic, and PTC anticipates most of them will transition to SEPHIENCE over time. The once-daily oral formulation and higher efficacy are expected to aid this conversion. Net pricing aligns with expectations based on a 45-kilogram patient.

Despite these positive developments, PTC faces broader revenue headwinds. The company reported $1.01 billion in revenue over the past year, a 43% year-over-year decline, with analysts forecasting further sales reduction of 26% in the current year. The stock currently trades slightly above its Fair Value of $66.62, making it one of the moderately overvalued names in the biotech sector. Two analysts have revised earnings downwards for the upcoming period, and there are 10+ key InvestingPro Tips available for PTCT.

Beyond SEPHIENCE, PTC outlined a wide pipeline spanning Huntington's disease, Friedreich's ataxia, gene therapy, and inflammation. CEO Klein expressed optimism about the Phase III completion but also discussed the possibility of earlier approval based on broader data packages. The company recently acquired ST-920, a Fabry gene therapy asset at the biologics license application stage, valuing its one-time dosing, lack of immunosuppression, and potential to replace standard enzyme replacement therapy.

PTC believes its own Fabry expertise and gene therapy experience can aid in the development and commercialization of this asset.